Roche at ESMO, 08 - 12 Sep 2017 Madrid
Welcome to Roche at ESMO 2017
The annual ESMO Congress is the leading event for oncology professionals in Europe to learn about the most recent breakthroughs in cancer research, innovative treatments and ongoing investigations.
ESMO 2017 - Sept 8-12, Madrid, Spain
Congress resources include Roche oral presentations, posters, symposia and meet the investigator (MTI) presentations. Please click here access further content from ESMO 2017.
Latest on Medically from ESMO 2017
ESMO 2017 symposium - What would you do?
Chapters I-VI: ESMO 2017 symposium - What would you do? Finding the optimal treatment for HER2 positive early breast cancer
ESMO 2017 CIT symposium: Are you geared up to surf the cancer immunotherapy waters?
Chapters A I/IV, B I/VII, and C I/V, ESMO 2017 CIT symposium chapters: Are you geared up to surf the cancer immunotherapy waters?
ESMO 2017 oral presentation- Clinical efficacy of atezolizumab in PD-L1 selected subgroups defined by SP142 and 22c3 IHC assays in 2L+ NSCLC: results from the randomized OAK trial
This analysis of the phase III OAK study evaluated the overlap between 22c3 and SP142 populations. Additionally, it assessed the efficacy of atezolizumab in SP142 and 22c3 defined PD-L1 subsets, including in PD-L1 negative subgroups.
ESMO 2017 oral presentation- Primary results from the Phase III ALUR study of Alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)
The phase III ALUR study directly compared Alectinib with standard chemotherapy in patients with advanced metastatic ALK+ NSCLC who had progressed on Crizotinib treatment. The primary efficacy and safety data are presented here.
ESMO 2017 oral presentation- Alectinib vs Crizotinib in treatment-naïve ALK+ NSCLC
The phase III ALEX study comparing Alectinib with Crizotinib in patients with previously untreated, advanced ALK-positive NSCLC was presented at ASCO 2017. Here we focus on the CNS efficacy.
ESMO 2017 MTI- Reshaping the treatment of mCRC with cancer immunotherapy combinations
Watch a video of Johanna Bendell discussing the latest advancements in the treatment of mCRC with cancer immunotherapy
ESMO 2017 Symposium - Comprehensive genomic profiling in clinical practice and beyond
This seminar describes comprehensive genomic profiling in clinical practice, a discussion on the importance of tumour location or pathway-driven clinical decisions and the pivotal role genomic profiling can have. ▼pembrolizumab, ▼afatinib, ▼osimertinib, ▼tofacitinib, ▼metformin, ▼ado-trastuzumab emtansine, ▼tiotropium bromide, ▼imatinib, ▼pertuzumab, ▼cobimetinib, ▼vismodegib, ▼alectinib: ▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please see safety reporting on the contact us page via the site menu.
ESMO 2017 symposium - Cancer immunotherapy in TNBC: targeting unmet need
Chapter I/IV - Watch Joyce O' Shaughnessey ask the audience to take part in a survey on their personal use of cancer immunotherapy in TNBC